Cancer is a complex progressive multistep disorder that results from the accumulation of genetic and epigenetic abnormalities, which lead to the transformation of normal cells into malignant derivatives. Despite enormous progress in the understanding of cancer biology including the decryption of multiple regulatory networks governing cell growth and death, and despite the possibility of analyzing (epi)genetic deregulation at the genome-wide scale, cancertargeted therapy is still the exception. In fact, to date there are still far too few examples of therapies leading to cure; treatment-derived toxicity is a major issue, and cancer remains to be one of the largest causes of death worldwide. The purpose of this review is to discuss the state of the art of cancer therapy with respect to the key issue of any treatment, namely its target selectivity. Therefore, we recapitulate and discuss current concepts and therapies targeting tumorspecific features, including oncofusion proteins, aberrant kinase activities and epigenetic tumor makeup. We analyze strategies designed to induce tumor-selective death such as the use of oncolytic virus, tumoricidal proteins (NS1, Eorf4, apoptin, HAMLET (human a-lactalbumin made lethal to tumor cells)) and activation of signaling pathways involved in tumor surveillance. We emphasize the potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, an essential component of the evolutionary developed defense systems that eradicate malignant cells. Finally, we discuss the necessity of targeting tumor-initiating cells (TICs) to avoid relapse and increase the chances of complete remission, and describe emerging concepts that might provide novel avenues for cancer therapy.
Introduction
Cancer results from the accumulation of genetic and epigenetic alterations that drive the transformation of a normal cell toward a malignant derivative. This process shapes each tumor in such a dynamic and unique way that it is extremely difficult to determine the alterations that cause, maintain and spread the disease (Greenman et al., 2007; Wood et al., 2007) .
Historically, solid tumors have been treated by surgery for the past 4000 years (http://www.cancer.org/ docroot/CRI/content/CRI_2_6x_the_history_of_cancer_ 72.asp?sitearea ¼ ). It was only after the discovery of X-rays at the end of the nineteenth century that radiotherapy emerged as a novel therapeutic approach. Whereas localized tumors could be treated by focal therapy, extensive or metastatic tumors and hematological malignancies required the development of systemic anticancer therapies. Initial efforts in anticancer drug discovery started in the mid-twentieth century based on the observation that cytotoxic agents could be used to kill cells displaying high proliferation rate. To date, surgery, radiotherapy and standard systemic chemotherapy still comprise the standard treatment in a majority of proliferative diseases. Indeed, novel chemotherapeutic (genotoxic) compounds are continuously being developed, despite the induction of serious side effects arising from the damage caused to normal tissue. Although initially the development of anticancer therapies relied on empirical observations, the current challenge is to develop novel therapeutic paradigms exploiting the knowledge derived from molecular, cellular and systems biology studies of tumor formation and progression (Shipley and Butera, 2009; Zhenchuk et al., 2009) . Despite the pleiotropic nature of tumors, several characteristics are shared by almost all malignancies namely: self-sufficiency in growth signals, evasion from apoptosis/immunosurveillance, insensitivity to growth inhibitory signals, limitless replicative potential, sustained angiogenesis and tissue invasion/ metastasis; as well as metabolic, mitotic, oxidative and DNA damage stress (Hanahan and Weinberg, 2000; Luo et al., 2009) . Consequently, a plethora of therapeutic approaches targeting the corresponding pathways/key players that support or are essential for tumor development are being developed and explored (Ferrara et al., 2004; Bianco et al., 2007; Berdis, 2008; Lane and Chabner, 2009; Desgrosellier and Cheresh, 2010; Tennant et al., 2010) (Figure 1 ). However, irrespective of the accumulating knowledge on tumor-specific features, at present the corresponding targeted therapies have only in rare cases led to cure. Indeed, the first curative cancer therapy that could be understood from the underlying biology concerns cancers with very specific somatic gene aberrations, such as defined chromosomal translocations in a subtype of acute leukemia (Melnick and Licht, 1999) . The therapeutic success was due to the removal of the cause of the malignancy, as was shown for acute promyelocytic leukemia (APL), which is caused by the formation of leukemogenic fusion proteins in hematopoietic progenitors (Melnick and Licht, 1999) . Treatment of APL patients with compounds that eradicate the leukemogenic fusion protein (all trans-retinoic acid (ATRA), arsenic trioxide; see below) cures most of the patients (Kogan, 2009; Nasr et al., 2009) . However, as a vast majority of cancers arise as a result of the accumulation of multiple (epi)genetic mutations, only in very particular cases the identification and subsequent targeting of a specific aberration may be feasible. Nevertheless, the example of APL demonstrates that a targetable 'achilles heel' of a given tumor can, in principle, be found.
The conceptual basis of this review is the argument that the major challenges in cancer therapy are: (1) the selective eradication of cancer cells, (2) the discovery of robust biomarkers for predicting therapeutic response to a given therapy and (3) the identification and targeting of tumor-initiating cells (TICs), which might constitute a highly dangerous compartment of a tumor that needs to be eliminated for complete remission. In the following sections we analyze the conceptual basis of current cancer therapies with respect to cancer selectivity and discuss known compounds, targets and pathways that can be exploited to achieve tumor-selective killing.
Current therapeutic paradigms to treat cancer
Attacking hallmarks of cancer Targeting factors indispensable for tumor development. Cancer is mainly the result of pleiotropic and usually multifactorial events. However, tumors display certain common characteristics, some of which have been and are at the basis of anticancer drug development ( Figure 1 ). Although it is not on the focus of this review to enter in detail along these lines of therapy, this section briefly summarizes current approaches that target three features of tumor growth, namely self-sufficiency in growth signals, sustained angiogenesis (neovascularization) and resistance to apoptotic stimuli.
Self-sufficiency in growth signals: A key feature of normal cell proliferation is the fact that normal cells require mitogenic signals in order to switch from a quiescent to a proliferative state. Under normal conditions, soluble mitogenic factors are not cell autonomously produced but are rather secreted by a different cell type. In contrast, a majority of tumor cells are capable of producing their own growth signals, thus promoting uncontrolled proliferation. Moreover, it has been shown that cancer cells can overexpress cell surface receptors involved in the transduction of growth signals as well as display ligand-independent signaling. These two characteristics have been reported for the epidermal growth factor receptors, which are transmembrane tyrosine kinase receptors involved in cell proliferation and survival (Yarden and Ullrich, 1988) . Epidermal growth factor receptor was the first molecular target for which monoclonal antibody (cetuximab) was developed for cancer therapy. The interaction with cetuximab promotes receptor internalization and degradation, thus blocking downstream signaling pathways involved in cell proliferation/differentiation, invasion, angiogenesis and apoptosis (Masui et al., 1986; Martinelli et al., 2009) . Cetuximab has been already approved for treatment of advanced head and neck squamous cell carcinoma and metastatic colorectal carcinoma. A second-generation monoclonal antibody (panitumumab) binds with high affinity to epidermal growth factor receptor, preventing receptor dimerization, Figure 1 Tumor-specific features targeted for cancer therapy. General features of tumor development are depicted as red spheroids. Blue spheroids exemplify factors/processes that are integral components of the corresponding feature and which are currently being targeted for cancer therapy; numbers refer to the following publications: (1) Tennant et al., 2010; (2) Desgrosellier and Cheresh, 2010; (3) Lessene et al., 2008 (4) Lane and Chabner, 2009; (5) Bianco et al., 2007; (6) Granchi et al., 2010; (7) Ferrara et al., 2004 and (8) Berdis, 2008. Novel paradigms for cancer therapy V Pavet et al phosphorylation and signaling, and thus inhibiting proliferation and promoting apoptosis. Panitumumab has been approved for the treatment of metastatic colorectal cancer showing preliminary activity in phase I/II clinical trials, and phase III clinical trials are currently ongoing (Van Cutsem et al., 2007) . An interesting addition to this concept is that rexinoids exclusively exert their apoptotic action under conditions in which growth factor signaling is impaired (Shankaranarayanan et al., 2009) , suggesting that the combination of both anticancer treatments might be an attractive strategy. Although the clinical activity of cetuximab and panitumumab antibodies has been consistently reported, tumors with activated K-RAS present little to no response to therapy, and potentially mutations in B-raf might have the same effect (Lievre et al., 2006; Di Nicolantonio et al., 2008; Karapetis et al., 2008) . Other potential markers of response to these compounds include polymorphisms of the cyclooxygenase (Lurje et al., 2008) , and the FCGR2A and FCGR2B (Fc g receptors) genes . Larger trials including biomarker analysis are required to validate these markers as predictors of response to therapy, thus allowing a more precise identification of patients who would profit from this therapeutic approach. Sustained angiogenesis: Solid tumors frequently activate neovascularization pathways (angiogenesis) to overcome death by nutrient/oxygen depletion. A tumor-induced switch of its microenvironment to an angiogenic state, in which several proangiogenic factors are upregulated, characterizes this survival phenomenon. Among those, vascular endothelial growth factor (VEGF) represents a major mediator of neovascularization. In general terms, antiangiogenic cancer therapy seeks to promote a poor vascularization within the tumoral mass, resulting in insufficient perfusion and promoting cell death. Two different kinds of agents have been developed to target the VEGF system, including those directly binding VEGF ligands, thus avoiding their interaction with the receptors (VEGFR), and those directly binding VEGFR (Grothey and Galanis, 2009 ). The first validated antiangiogenic agent for cancer treatment was a monoclonal antibody (bevacizumab) targeting VEGF (Ferrara et al., 2004) . This antibody, which clears VEGF from circulation thereby limiting the formation of tumor vessels supporting tumor growth, was the first monoclonal antibody approved in combination with chemotherapy for treatment of patients with metastatic colorectal cancer (Bergers and Benjamin, 2003) . More recently, it has been approved for treatment of metastatic renal cancer, glioblastoma, metastatic breast cancer and non-squamous non-small cell lung cancer. Besides participating in tumor neovascularization, the VEGF pathway is an essential component of normal development and participates in the homeostasis of many organs in the adulthood. Therefore, a broad spectrum of side effects is associated with antiangiogenic therapies, such as hypertension, hemorrhage, arterial trombo-embolic events, proteinuria, renal dysfunction or gastrointestinal perforation. Although most of these adverse effects are manageable, in particular cases side effects can be very serious and life threatening, depending on tumor type/localization, the age of the patient, clinical settings and combinatorial therapies (Chen and Cleck, 2009 ). To date, neither biomarkers of efficacy nor markers of early toxicity for anti-VEGF therapy exist (Jain et al., 2009 ). This constitutes a major challenge in the field that will require a combined effort among basic and applied research in order to achieve this important goal.
Evasion from apoptosis: Apoptosis is a mechanism having a key role not only during mammalian development but also in adult organisms. Maintaining a proper regulation of apoptotic responses is mandatory for assuring proper tissue development and homeostasis, while altered responses to normal apoptotic signals is one of the hallmarks of cancer, often related to defects in the apoptotic machinery in cancer cells. Triggering of apoptosis can be achieved via the activation of two different pathways, the extrinsic and the intrinsic apoptotic cascades (Figure 2 ). The extrinsic pathway operates through the activation of membrane-bound death receptors (DRs). The activation of the extrinsic cascade by the administration of receptor agonists, as well as sensitization to this apoptogenic pathway, are important strategies that are being explored for cancer therapy (discussed in the section 'Exploiting the endogenous tumor-surveillance system for cancer therapy'). The intrinsic pathway involves disruption of the mitochondrial membrane integrity and is tightly controlled by pro-and anti-apoptotic proteins of the B-cell lymphoma-2 (BCL-2) family, which comprises 5 antiapoptotic (BCL-2, BCL-XL, BCL-W, MCL-1 and A1) and 10 proapoptotic (BAX, BAK, BIM, BID, PUMA, NOXA, BAD, BMF, HRK and BIK) proteins. In addition, proteins known as inhibitors of apoptosis (IAPs) also have a crucial role through inhibiting the apoptotic cascade by either blocking caspase activation or promoting caspase degradation by the proteosome. To date, eight IAPs (XIAP, IAP-2, cIAP-1, cIAP-2, ML-IAP, NAIP, survivin and apollon) have been described, with X-linked IAP (XIAP) displaying the most potent antiapoptotic effect. However, endogenous IAP inhibitors, such as Smac (second mitochondriaderived activator of caspase)/DIABLO (diablo homologDrosophila), Omi/HtrA2 and XIAP-associated factor-1 (XAF1), can antagonize the antiapoptotic activity of IAPs. Finally, it is the interplay between, and equilibrium among, pro/anti-apoptotic proteins and IAP/IPA inhibitors that dictate cell fate in response to diverse apoptotic triggers.
As resistance of cancer cells to apoptosis has been related to enhanced expression of antiapoptotic proteins from both the BCL-2 family and IAPs, strategies seeking to antagonize the action of these molecules (BCL-2 and IAP inhibitors) have been extensively studied for cancer therapy.
BCL-2 inhibitors: The overexpression of the antiapoptotic protein BCL-2 in several types of cancer promotes cancer cell survival without affecting cell proliferation. This supports the hypothesis that restoring apoptosis in cancer cells by modulating the levels/function of Novel paradigms for cancer therapy V Pavet et al antiapoptotic proteins could help to remove cancerous cells. The BCL-2 family is characterized by specific homology regions named BH (BCL-2 homology) domains. Whereas all five antiapoptotic proteins and BAX/ BAK proapoptotic proteins present four BH domains (BH1, BH2, BH3 and BH4), the remaining eight proapoptotic proteins only present the BH3 domain (thus called BH3-only proteins). The BCL-2 antiapoptotic protein contains a BH3 binding groove that accommodates the BH3 domain of proapoptotic proteins, therefore impeding their action and blocking apoptosis. This structural feature provides the platform to develop peptides and chemical compounds that bind to the groove of the antiapoptotic protein, thus reliving the apoptotic block and promoting cell death (Lessene et al., 2008) . However, initial phase I and II clinical trials administering the BH3-mimetic gossypol were not encouraging. More recently, gossypol derivates and analogs have been developed. Among those, AT-101 is well tolerated and is currently tested in phase I/II clinical trials for prostate, lung and esophageal cancer, glioblastoma and B-cell lymphoproliferations. A semisynthetic gossypol analog (apogossypolone) with improved pharmacologic activity displayed tumoricidal activity in vitro and in vivo (Sun et al., 2008) . Interestingly, phase I clinical trials of a broad-spectrum inhibitor of the antiapoptotic Bcl-2 family (obatolax mesylate) showed that it is well tolerated, has biological activity and displays modest single-agent activity in heavily pretreated chronic lymphocytic leukemia patients (Tan et al., 2009) . Another strategy involves the use of an antisense oligonucleotide to target Bcl-2 mRNA (oblimersen sodium). The administration of this molecule in different combinatorial approaches (that is, with chemotherapy among others) showed activity for treatment of chronic lymphocytic leukemia and malignant melanoma in phase III clinical trials (Bedikian et al., 2006; O'Brien et al., 2007) .
IAP inhibitors: Overexpression of IAPs can confer resistance to a broad variety of apoptotic stimuli and constitutes a marker of poor prognosis in hematologic and solid cancers. Suppression of IAP activity/levels was shown to either directly trigger apoptosis or sensitize cancer cells to proapoptotic triggers currently used as anticancer treatment. Thus, strategies mimicking the action of endogenous IAP inhibitors such as Smac (SMAC mimetics), blocking the interaction of XIAP (Fulda, 2009 ). The interaction of the endogenous Smac protein with IAPs is mediated by its N-terminal tetrapeptide AVPI (Ala1-Val2-Pro3-Ile4). Based on structural information, several small molecules mimicking AVPI (and thus Smac inhibitory function) were designed in order to derive stable compounds that could be administered as therapeutics. These include monovalent Smac-derived peptides as well as mono-and bi-valent Smac-derived peptidomimetics. To date, four Smac mimetic compounds (GDC-0152, LCL161, AEG40826/HGS1029 and AT-406) have been approved for clinical trials (Flygare and Fairbrother, 2010) . Whether mono-or bi-valent molecules would present the higher activity/less toxic effects in humans remains to be established.
Destroying the cause of cancer and inducing differentiation: oncofusion proteins as targets. Somatic chromosomal rearrangements can cause the formation of abnormal fusion proteins, leading to cancer as a result of the deregulation of key factors involved in the control of cell growth, survival or death. One of the best understood fusion proteins is the prototypic PMLRARa (promyelocytic leukemia-retinoic acid receptor) that causes APL and originates from the translocation t(15;17)(q22;q21). This chromosomal rearrangement juxtaposes a portion of the PML and RARA genes (other X-RARa oncofusions are similarly leukemogenic; Melnick and Licht, 1999) . The aberrant PML-RARa fusion protein displays a plethora of molecular features distinct from RARa, including altered homo-and hetero-oligomerization, different DNA-binding site repertoires, changes in the interaction with key factors like p53 or abnormal recruitment of epigenetically active complexes to RARa targets (Grignani et al., 1998; He et al., 1998; Lin et al., 1998 Lin et al., , 2004 Di Croce et al., 2002; Bernardi et al., 2004; Insinga et al., 2004; Kamashev et al., 2004; de Stanchina et al., 2004; Zeisig et al., 2007) . However, which of these abnormal characteristics, if not all, are responsible for the initiation of leukemogenesis has remained elusive. Another open question that was raised in view of the long latency for induction of a full leukemic phenotype observed in murine models, is whether or not a secondary mutation is required to develop the disease ('second hit' hypothesis) (Yuan et al., 2001; Schessl et al., 2005; Yamashita et al., 2005) . Importantly, the presence of the PML-RARa oncofusion protein remains essential for maintenance of the leukemic phenotype.
Initially, it was thought that ATRA treatment would cure patients because of the differentiation of blasts ('differentiation therapy'). This differentiation is believed to occur as a result of the activation of RARatarget genes by ATRA binding to PML-RARa, which would dissociate abnormally bound corepressor-histone deacetylase (HDAC) complexes from the fusion protein.
However, it was subsequently observed that liposomal ATRA as single agent induced the degradation of the leukemogenic protein itself, achieving complete remission in human APL patients (Tsimberidou et al., 2006) . Additional insight into the critical role of the fusion protein was obtained from a mouse model of APL, in which leukemia cells were serially transplanted from one animal to another, resulting in transmission of the disease. In this model, a sub-population of the leukemic cells (referred to as leukemia-initiating cells (LICs)) persisted after ATRA treatment, although ATRA induced differentiation in the bulk of cells. However, combining ATRA with arsenic trioxide (an agent approved for second-line APL therapy) completely wiped out the fusion protein and eradicated both LICs and bulk APL cells, and led to complete remission (Nasr et al., 2008) .
The discovery that PML-RARA is the cause of APL coincided with the identification of RARA as a gene coding for the RAR-a, and provided a rationale for the use of ATRA as an agent that specifically attacks the fusion protein. To date, ATRA-differentiative capacity and ATRA/arsenic-induced degradation of PMLRARa fusion protein is believed to account for the therapeutic response. From a conceptual point of view, these results argue that identifying and targeting cancercausing aberrant proteins would ultimately lead to cure. Unfortunately, APL is a rather specific case in which the fusion protein generates a pre-leukemic state, and as little as one additional 'hit' is believed to suffice for progression to the fully leukemic state. Moreover, the presence of the leukemogenic fusion protein remains essential for the disease to develop. In contrast, a vast majority of solid cancers display multiple (epi)genetic alterations and somatic mutations that increase during progression (Shah et al., 2009) , involving not only coding sequences but also non-coding RNAs. Furthermore, o10% of (epi)mutations found in tumors are indeed 'driver' mutations causally involved in tumorigenesis, whereas the rest are 'passenger' mutations that neither contribute to the onset nor to the development of the disease (Greenman et al., 2007; Wood et al., 2007) . It is conceivable that tumor cells become independent of the initial (epi)mutation(s) as a result of the inherent genetic instability. As patients are usually diagnosed with a developed tumor, it is unlikely that the search and targeting of cancer-causing aberrations might be a general applicable therapeutic rationale (Huang et al., 1988; Warrell et al., 1993; Soignet et al., 1998) .
Inhibiting tumor-activated kinases that regulate cancer cell proliferation and survival. Deregulation of kinase activity is a major mechanism by which cancer cells evade physiological constraints controlling cell growth and survival. The drugability of these molecules and the Novel paradigms for cancer therapy V Pavet et al dependency of tumor cells on kinase activity for survival make them important targets for cancer therapy. Aberrant kinase activity can result from the generation of fusion proteins formed by chromosomal translocations or by aberrant expression/activity of the protein itself. Chronic myeloid leukemia (CML) represents a well-characterized example for the expression of an aberrant kinase. In CML, the chromosomal translocation t(9;22)(q34;q11) generates the 'Philadelphia (Ph) chromosome' harboring a fusion between the ABL1 tyrosine kinase gene on chromosome 9 and the 'breakpoint cluster region' (BCR) on chromosome 22, resulting in the expression of a BCR-ABL fusion protein.
Like PML-RARa in the case of APL, the BCR-ABL protein is not only the initial cause but also the singular driver of CML throughout its course, thereby identifying it as an ideal drug target. BCR-ABL displays constitutive kinase activity, which results in the deregulated activation of signaling cascades that promote cell proliferation and survival (Shtivelman et al., 1985; . The first compound that successfully inhibited the aberrant BCR-ABL kinase activity and displayed clinical efficacy was imatinib mesylate (Druker, 2001) , which has considerably increased the survival rate of CML patients (88% for 6 years) and decreased the need of hematopoietic stem cell transplantation (Hochhaus et al., 2009) . At present, two other inhibitors have been approved and can be used to treat patients refractory to imatinib Cortes et al., 2007; le Coutre et al., 2008) . Notably, although imatinib was originally designed to specifically target BCR-ABL, this compound also inhibits the c-Abl, DDR1 (discoidin domain receptor family, member 1), platelet-derived growth factor receptor and c-kit kinases, and has shown therapeutic activity for gastrointestinal stromal tumors, which often overexpress c-kit (Demetri et al., 2002) .
The clinical success of imatinib has inspired the mapping of the full range of abnormal protein kinases present in human cancers (tumor kinome), and a large repertoire of kinase inhibitors is continuously being expanded (Futreal et al., 2004; Janne et al., 2009) . Ongoing activities try to match cancer kinome aberrations with the target profiles and selectivity of these inhibitors.
Several conceptual issues have to be considered when using kinases for drug targeting. The validation that the kinase to be targeted (like in CML) is the singular driver and/or indispensable for persistence of the disease should be provided. As de novo or acquired resistance to these kinds of inhibitors has been reported, strategies to minimize this risk have to be developed. In this respect, the identification of molecular markers of sensitivity/resistance to specific compounds is a challenge. Finally, at present it is not possible to predict 'if' and 'how many' matches between increased kinase activity in cancers and kinase inhibitors can be found; technological advances like fragment-based drug discovery (Blundell et al., 2002) and crystallization of kinase-inhibitor complexes should accelerate and improve drug development. In summary, despite the proven clinical value of these drugs in the therapy of CML and gastrointestinal stromal tumors, key questions such as whether (an aberrant) a kinase or a set of kinase(s) can be identified as driver(s) of the disease, and whether the identified kinase is also required for the maintenance/survival of the corresponding TICs, remain to be answered. Moreover, as the mutational status of the tumor cell and the tumor microenvironment may modulate tyrosine kinase activity, their effect on the action of the inhibitor needs to be clarified (for extensive reviews about the cancer kinome and kinome (poly)pharmacology, see Zhang et al., 2009; Knight et al., 2010) .
Attacking the tumor epigenome. The term 'epigenetics' describes mitotically inheritable changes of gene expression that do not involve changes of the DNA sequence. This is achieved by DNA methylation of CpG dinucleotides and, in recent years, this term is also applied for the gene-regulatory potential of post-translational modifications of histones (Klose and Bird, 2006) . It is now well established that the epigenetic status of a cell is severely altered upon malignant transformation. Cancer cells concomitantly display global genomic DNA hypomethylation and gene-specific promoter hypermethylation. Whereas DNA hypomethylation may contribute to the tumorigenic process by inducing chromosomal instability and reactivation of transposons and oncogenes, hypermethylation of CpG islands may result in the silencing of tumor-suppressor genes, a hallmark during cancer onset and progression (Feinberg and Vogelstein, 1983; Gama-Sosa et al., 1983; Fraga and Esteller, 2005; Weber et al., 2005) . More recently, changes in the methylation pattern of DNA regions coding for micro-RNAs (miRs) that modulate the expression of oncogenes or tumor suppressors have been reported (Datta et al., 2008; Huang et al., 2009; Pallasch et al., 2009) . Inversely, it has been observed that oncofusion proteins can epigenetically silence miRs that are critically involved in lineage specification (Fazi et al., 2007) . Altogether, these studies argue that locally altered methyl-CpG densities can result in the deregulation of multiple regulatory pathways, which are relevant for tumorigenesis. Furthermore, abnormal function/ recruitment of histone-epigenetic modulators is also recognized to have a role in tumorigenesis (Feinberg and Tycko, 2004; Esteller, 2008) . Consequently, epigenetic enzymes have been identified as valuable drug targets, as aberrant DNA methylation and histone modifications can be reverted by the administration of epigenetic drugs ('epi-drugs').
Inhibitors of DNA methylation (cytosine analogs; 5-azacytidine and 5-aza-2 0 -deoxycytidine) are currently used for the treatment of myelodysplastic syndrome and the first two HDAC inhibitors, vorinostat and romidepsin, have been approved by the FDA for the treatment of cutaneous T-cell lymphoma (http://clinicaltrials.gov) (Drummond et al., 2005; Grant et al., 2007; Xu et al., 2007) . With the identification of large families of histone methyltransferases and demethylases The use of epi-drugs for therapy has both advantages and drawbacks. On the positive side is the fact that epienzymes are drugable, non-genotoxic and act transiently. The observation that a block of total HDAC activity is tolerable to cutaneous T-cell lymphoma patients reveals a high plasticity of epigenomes, particularly those of normal cells. Ideally, inhibiting the action of aberrant epi-enzymes would allow the reactivation of the epigenetically silenced endogenous defense systems. On the negative side are the problems to generate selective epi-drugs in the context of large families of epi-enzymes, and the presently incomplete knowledge about their (patho)physiological functions. Moreover, the transient action of epi-drugs may also be a disadvantage, as it could foster development of resistance. In this respect, the combination of several epigenetic activities is an option that is currently being explored. An entirely open question is the epigenetic makeup of TICs that may well differ from the bulk of tumor cells and represent particularly attractive targets.
Strategies to selectively kill tumor cells
Administration of virus and virus-derived proteins for cancer therapy. Several viruses, including species displaying an inherent tumor selectivity (that is, parvoviruses, vesicular stomatitis viruses, Newcastle disease virus), and engineered viruses (adenoviruses, herpex simple virus, measles virus) can replicate selectively in cancer cells, thereby leading to cancer cell-selective lysis (oncolysis). Oncolytic viruses displaying various mechanisms of action have been developed over the past 15 years. These include viral mutants, in which genes critical for viral growth in normal cells but not in tumor cells were deleted, pseudotyped viruses, in which normal viral tropism was ablated, and engineered viruses binding to specific surface receptors that are expressed exclusively/preferentially on tumor cells (Alemany et al., 2000; Khuri et al., 2000; Kirn, 2000; Fukuhara et al., 2005 Fukuhara et al., , 2009 Kasuya et al., 2005; Liu and Kirn, 2008; Dorer and Nettelbeck, 2009 ). Interestingly, oncolytic viruses can kill apoptosis-resistant tumor cells, and do not show cross-resistance with existing therapies. Although some promising results were observed in clinical trials, the predicted replication selectivity has not (yet) been reached. Reasons for this comprise the incomplete knowledge of the complex virus-cell interactions, the leakiness of cellular promoters in the viral genome and the interplay of the virus with the immune system (Liu et al., 2007) .
A second virus-based approach involves the exogenous administration of viral-derived proteins to induce tumor-selective cell death (Noteborn, 2009) . Such activities have been demonstrated for the adenovirusderived E4orf4, the parvovirus H1 protein NS1 and chicken anemia virus-derived apoptin (Guelen et al., 2004; Maddika et al., 2005; Maddika et al., 2006; Rohn and Noteborn, 2004) (Table 1) . During natural infection, these proteins orchestrate the cytolytic events that are requisite for successful spreading of the virus. Interestingly, it has been shown that overexpression of these viral-derived proteins is cytotoxic for tumor but not for normal cells.
The postulated mechanisms of action of these proteins are not fully elucidated and appear to be diverse. NS1 was shown to interact with casein kinase II of the host cell, thus inducing casein kinase II-dependent cytoskeletal changes that lead to apoptosis Rommelaere, 2006, 2007) . E4orf4 is an adenovirus protein that does not require the classical caspase Abbreviations: BCL-2, B-cell lymphoma-2; DR, death receptor; HAMLET, human a-lactalbumin made lethal to tumor cells; MDA-7, melanoma differentiation-associated gene-7; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand. '?' Stands for unknown.
Novel paradigms for cancer therapy V Pavet et al pathways in order to trigger cell death (Landry et al., 2006) , and it leads to changes in cell morphology (including multiple nuclei and increase in cell volume) that suggest a tumor cell-selective G2/M arrest, leading to mitotic catastrophe (Li et al., 2009a, b) . Finally, apoptin induces apoptosis in a wide variety of human cancer cell lines via classical apoptotic pathways (Rohn and Noteborn, 2004; Maddika et al., 2005 Maddika et al., , 2006 Backendorf et al., 2008) . Several independent in vivo analyses using human xenografted tumors have proven that administration of apoptin, as well as its recombinant version protein transduction domain 4 (PTD4)-apoptin, results in a significant reduction of tumor growth without major side effects (Peng et al., 2007; Sun et al., 2009 ). An important feature shared by these three viral-derived anticancer proteins is the fact that they do induce cell death in a p53-independent manner and that the tumoricidal activity is not affected by the overexpression of Bcl-2 (Table 1) . Hence, NS1, Eorf4 and apoptin circumvent blocks in the apoptosis machinery often observed in tumor cells and could induce alternative types of cell death (that is, mitotic catastrophe). Although these molecules could represent serious candidates for the development of novel anticancer paradigms, further insights into the molecular mechanisms by which these factors achieve tumor selectivity are essential for their validation and development as cancer therapeutics.
HAMLET: a cellular-derived complex displaying tumoricidal activity. The tumoricidal activity of a substance purified from human milk, a-lactalbumin bound to oleic acid (also referred to as 'human a-lactalbumin made lethal to tumor cells' (HAMLET)), was discovered by serendipity when the role of milk fractions on bacterial attachment to lung carcinoma cells was studied (Hakansson et al., 1995) . Apart from inhibiting bacterial attachment, this fraction also displayed tumoricidal activity and suggested a potential use of HAMLET as an anticancer agent (Table 1) . This complex has been reported to induce cell death in a plethora of cancer cell lines, whereas normal cells are resistant Hallgren et al., 2008) . It has been postulated that HAMLET might interact and perturb the functioning of the mitochondria (Kohler et al., 1999) , proteosome ) and histones , inducing features of multimembrane autophagosomes and suggesting that macroautophagy might contribute to tumor cell death . Although it has been demonstrated that normal and tumor cells display different features for the subcellular localization and internalization of HAMLET (suggesting the existence of active shuttling mechanisms), neither the receptors involved nor the mechanisms orchestrating the protein uptake have been identified. Despite limited knowledge on the molecular mechanisms orchestrating HAMLET action, two clinical pilot experiments using local treatment of skin papillomas and intravesical instillation of bladder cancer with HAMLET revealed that this complex displays tumoricidal activity in humans (Gustafsson et al., 2004; Mossberg et al., 2007; Noteborn, 2009) (Table 1) . That HAMLET has been proven active in vivo, and that no major toxic effects have been documented, is encouraging. However, as local administration is necessary, a very restrictive spectrum of cancer types can be targeted. Efforts to determine the molecular mechanisms underlying HAMLET-induced cell death and its cancer selective action are required in order to provide the molecular rationale(s) of its mode of action, hence expanding the spectrum of potential therapeutic targets to exploit the HAMLET-induced tumor-selective cell death pathway(s).
Exploiting the endogenous tumor-surveillance system for cancer therapy. Melanoma differentiation-associated gene-7 (mda-7): The expression of this human endogenous cytokine (also known as interleukin-24) was first described in normal melanocytes and keratinocytes, and later reported in tissues and cells of the immune system (Jiang et al., 1995; Wang and Liang, 2005) . The observation that the expression of this interleukin decreases during pathologic progression of melanocytes into melanomas suggested a potential role as tumor suppressor (Huang et al., 2001; Ellerhorst et al., 2002) . Although the exact biological functions of mda-7 are not fully elucidated, it is clear that it presents a dual role as a classical cytokine via its receptors and as a cytotoxic agent acting intracellularly in a receptor-independent manner (Sieger et al., 2004; Ekmekcioglu et al., 2008) . It has been demonstrated that whereas normal cells are not affected by mda-7 expression, it induces antiproliferative effects as well as downregulation of survival signals leading to apoptosis in several cancer cell lines by modulating different pathways (p38-mitogen-activated protein kinase (MAPK), protein kinase RNA-regulated (PKR), c-Jun-N-terminal kinase (JNK), b-catenin and phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathways). This interleukin also induces Fas/FasL signaling, thus supporting apoptosis via the extrinsic apoptotic cascade (Gopalan et al., 2005; Shanker et al., 2007) .
Besides its apoptotic potential in tumor cells, mda-7 also inhibits cancer cell migration and invasion, and displays a substantial antiangiogenic activity within tumors (Lebedeva et al., 2007) . Interestingly, phase I clinical trials using mda-7 as single agent for the treatment of malignant melanoma demonstrated significant activity and good tolerability (Lebedeva et al., 2007; Eager et al., 2008; Emdad et al., 2009) (Table 1) . However, it has been observed that subsets of tumor cells are either inheritably resistant to mda-7 or can acquire resistance upon exposure to the cytokine. Although some molecules/pathways participating in the acquisition of the resistant phenotype have been identified (that is, Bcl-2; activation of the kRas signaling pathway among others), neither the molecular basis underlying resistance in different cancer cells nor the molecular basis of tumor selectivity have been unraveled (Sarkar et al., 2008) .
Novel paradigms for cancer therapy V Pavet et al
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): TRAIL, a member of the extrinsic death pathway, is a type II trans-membrane protein that binds as a homotrimer to the extracellular part of its four membrane-bound TRAIL-specific receptors (Figure 2a ) with similar affinity. Among the four receptors, two DRs (death receptors DR4/TRAIL-R1 and DR5/TRAIL-R2) present an intracellular death domain that, upon TRAIL binding, recruits adaptor proteins (FADD (Fas-associated death domain)) and initiator caspases (procaspases-8/10), thereby transducing the apoptotic signal by activating the caspase cascade via the extrinsic pathway (Figure 2b) . In some cells, TRAIL will also operate by activating the intrinsic pathway, crosstalk mediated by the action of Bid (Figure 2b However, later reports indicated that this toxic effect, observed under in vitro culturing conditions, might result from the use of tagged-TRAIL (histidine, FLAG or leucine-tagged TRAIL), whereas the recombinant untagged version of the cytokine was nontoxic on normal cells (Lawrence et al., 2001; Qin et al., 2001) . Furthermore, recent studies have shown that whereas the tagged versions of TRAIL might result in toxicity on primary human hepatocytes in vitro, the same compounds displayed very modest toxic effect on hepatic explants obtained from healthy donors, indicating that the use of primary human hepatocytes as model for analyzing toxicity effects might not be the most suitable (Volkmann et al., 2007) . The same report shows that hepatic explants obtained from patients suffering from hepatic diseases (hepatitis C viral infections or liver steatosis) were susceptible to the toxic action of the cytokine, suggesting that the clinical use of TRAIL might be cautiously considered in patients presenting hepatic inflammatory diseases.
Despite our limited understanding of the molecular basis of the cancer-selective action of TRAIL, multiple clinical trials have been/are being conducted in order to define its therapeutic potential as a single agent or in combinatorial settings (Table 2 ; http://clinicaltrials.gov). To date, three principal pharmacological strategies have been developed, including the administration of recombinant human TRAIL (Apo2L/AMG951); the use of activating humanized antibodies directed against the death receptors DR4 (mapatumumab/HGS-ETR1) or DR5 (lexatumumab/HGS-ETR2/AMG655); and the adenoviral delivery of the TRAIL coding sequence into tumor cells (Ad5-TRAIL) (Holoch and Griffith, 2009 ). Initial reports from phase I and II trials indicate that, contrary to what was expected based on in vitro data, hepatic or renal toxicity were not clinically significant and, when observed, they were modest and usually in patients presenting hepatic problems as baseline. Indeed, the most common adverse effects included nausea, fatigue, constipation and leucopenia (in B10-20% of the patients) and did not lead to the discontinuation of the treatment. Furthermore, no immunogenicity against mapatumumab or lexatumumab has been observed. Clinical responses ranging from stable disease, partial responses and even a complete response have been reported after administering either untagged versions of recombinant human TRAIL or antibodies targeting death receptors as monotherapy (Plummer et al., 2007; Tolcher et al., 2007; Greco et al., 2008; Hotte et al., 2008; Leong et al., 2009; Mom et al., 2009; Trarbach et al., 2010; Wakelee et al., 2010) . Taken together, safety results and clinical responses encourage further diseasedirected assays of these agents.
These clinical trials have also indicated that several human tumors might be resistant to TRAIL monotherapy. Moreover, proliferative effects in response to TRAIL have been reported in vitro using glioma and small cell lung cancer cell lines (Belyanskaya et al., 2008; Vilimanovich and Bumbasirevic, 2008) (Figure 2c) . In other case, mice in which Bcl-xl-overexpressing Colo357 pancreatic ductal carcinomas were orthotopic transplanted formed more metastases upon TRAIL treatment (Trauzold et al., 2006) , and finally two studies with blasts from leukemia patients treated ex vivo report effects of TRAIL exposure ranging from triggering of cell death to induction of cell proliferation (Ehrhardt et al., 2003; Hasegawa et al., 2005) . TRAIL-induced proliferative effect has also been reported in synoviocytes from human rheumatoid patients who exhibit a poorly understood biphasic response to the cytokine, as it triggers death in an initial phase but support proliferation for the persisting/resistant cell fraction (Morel et al., 2005) . These results suggest that in the case of TRAIL resistance in cancer cells or specific inflammatory conditions, cells may switch the TRAIL response from apoptotic to proliferative. Although there is evidence that the nuclear factor-kB, p38, JNK and extracellular signal-regulated kinase pathways modulate the proliferative responses, it will be important to precisely define which factors and complexes (for example, death-inducing signaling complex members) are modulating two different responses to the same trigger (Harper et al., 2001; Ehrhardt et al., 2003; Varfolomeev et al., 2005; Belyanskaya et al., 2008; Vilimanovich and Bumbasirevic, 2008) (Figure 2c ). Moreover, even if an extensive number of molecules and mechanisms have been shown to participate in Novel paradigms for cancer therapy V Pavet et al Abbreviations: ANR, active not recruiting; C, completed; CRC, colorectal cancer; DR, death receptor; HCC, hepatocellular carcinoma; IFN-g; interferon-g; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung carcinoma; R, recruiting; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
Novel paradigms for cancer therapy V Pavet et al TRAIL-induced apoptosis and/or resistance in cancer cells (Zhang and Fang, 2005; Thorburn et al., 2008 ), it has not been possible to determine a single 'common factor' regulating TRAIL sensitivity in different types of tumors. Thus, these data suggest that a 'master regulator' triggering the switch from TRAIL resistance in normal cells to TRAIL sensitivity in tumors may not exist, but that it is rather a balance between different molecules and/or signaling pathways that will dictate the final growth or apoptosis-stimulatory activity of the cytokine. Taken together, data from basic research and clinical trials not only support the promise of cancer-selective apoptosis through activation of the TRAIL pathway, but also point out the need for extensive and carefully monitored studies in which the regulatory networks controlling the apoptotic and proliferative activities of this signaling are deciphered. Therefore, an urgent need is to identify biomarkers and sensitivity assays that permit to recognize patients who will profit from the therapeutic potential of this pathway and would not suffer from potential non-desired proliferative effects. It is important to emphasize that resistance to TRAILinduced apoptosis in cancer does not represent a roadblock for the use of the TRAIL signaling pathway as a therapeutic target. Indeed, it is well established that resistance can be relieved by a poorly understood phenomenon generally referred to as 'sensitization'. A plethora of sensitizing agents, including ionizing radiation, chemotherapeutic drugs, cytokines as well as HDAC, proteosome or phosphatidylinositol-3-kinase (PI3K)/Akt inhibitors can reverse the TRAIL-resistant phenotype (Figure 3) (Altucci et al., 2001 (Altucci et al., , 2005 Clarke et al., 2004; Insinga et al., 2005; Nebbioso et al., 2005; Newsom-Davis et al., 2009) . Furthermore, administration of inhibitors of the canonical nuclear factor-kB pathway, which has been shown to regulate resistance to TRAIL-induced apoptosis, induces sensitization of cancer cells to TRAIL (Ravi et al., 2001) . Interestingly, first reports from clinical trials combining mapatumumab with cisplatin and gemcitabine have demonstrated that this combination can be safely administered. Response numbers of this phase I trial were encouraging, as 26/37 patients showed a decrease in tumor lesions and 12 showed partial response. However, it is worth highlighting that the value of these numbers is limited given the non-randomized nature of the study.
Recombinant proteins and humanized antibodies are without doubt well established as therapeutics. Nevertheless, the inherent disadvantages of proteins (synthesis, purity, stability, production costs) provide a strong rationale for the development of more 'drug-like' activators of the TRAIL cascade. In that regard, the recent demonstration that specific multivalent DR5-selective synthetic peptides activate the TRAIL pathway in a tumor-selective manner even when combined with sensitizing compounds is a promising development. Moreover, these novel TRAIL DR5/mim mimics displayed anticancer activity in vivo as single agents in human tumor xenograft models (Figure 4) , opening new avenues to exploit the TRAIL pathway as anticancer treatment (Pavet et al., 2010) .
In summary, the observations that TRAIL (1) is part of an evolutionarily shaped endogenous tumor defense system, (2) induces apoptosis in a tumor-selective manner, (3) resistance can be overcome by various modes of 'sensitization', (4) displays activity in preclinical models (human tumor xenografts) (5) shows promising results in clinical trials and (6) can be used in at least four different pharmacological modes, identify the TRAIL cascade as one of the most exciting and promising pathways for the development of nongenotoxic cancer-selective therapeutics. To date, 6 clinical trials have been completed and data have been released, whereas 25 targeting the TRAIL pathway alone or in several combinatorial approaches are currently ongoing (Table 2) . It is worth mentioning that initial trials have enrolled patients mostly bearing advanced, relapsed, refractory cancers. Therefore, the tumoricidal efficiency of inducers of TRAIL pathway in less-advanced stages of the malignancy is still unknown. Moreover, it has been very recently demonstrated that TRAIL in combination with all-trans-retinyl acetate can Figure 3 A plethora of compounds modulate the sensitivity to TRAIL-induced apoptosis by regulating the expression/activity of different molecular players along the pathway. Known molecular players involved in TRAIL-induced apoptosis are depicted in the pink circle (TRAIL, DISC, pro-/anti-apoptotic proteins, mitochondria, XIAPs and IAPs). Compounds displayed in concentric partial circles (retinoids, chemo-radiotherapy, Smac mimetics, HDAC inhibitors, proteosome inhibitors, rexinoids, cAMP and demethylating agents) synergize with the TRAIL-apoptotic pathway by regulating the expression/activity of the molecular players depicted in the pink circle. As evidenced, whereas some compounds modulate TRAIL sensitivity by targeting different components of the cascade (that is, HDAC inhibitors concomitantly modulate the expression of TRAIL, DISC members as well as pro-/antiapoptotic proteins and induce mitochondrial activation), others present a more restricted action (that is, Smac mimetics regulate the activity of IAPs).
Novel paradigms for cancer therapy V Pavet et al efficiently target premalignant tumor cells (Zhang et al., 2010) . Whether TRAIL-based therapies may be utilized for treatment of pre-neoplastic lesions or preventive therapy following surgery is an issue that deserves further consideration.
Emerging concepts for cancer therapy Dependence receptor signaling: new option for cancer therapy?. Dependence receptors comprise a family of more than 12 membrane-bound receptors that are grouped together according to common function rather than structural similarities. These receptors support cell differentiation, survival and migration ('positive signaling') when bound to their cognate ligands. Importantly, the ligand-free receptor induces an entirely distinct signaling cascade, resulting in cell death ('negative signaling'). Although initially identified as implicated in nervous system development, these receptors were subsequently shown to be involved in tumor progression (Mehlen and Puisieux, 2006; Goldschneider and Mehlen, 2010; Fombonne and Thibert, 2010) . More recently, dependence receptors have been also described as modulators of the survival of endothelial cells, therefore promoting angiogenesis (Castets et al., 2009) .
The concept underlying the dual role of dependence receptors is that this coexistence allows them to not only regulate normal developmental process (that is, neural tube formation), but also to act as a safeguard mechanism to prevent tumor progression. As ligandfree dependence receptors induce apoptosis, they are believed to act as tumor suppressors, as hyperproliferative or metastatic cells exposed to an abnormal liganddepleted or -deficient environment would undergo apoptosis. Consistently, tumor cells would either reduce/deplete levels of dependence receptors or secrete high levels of the ligands in order to avoid cell death. This hypothesis is supported by the observations that reduced levels of several dependence receptors have been reported in different types of cancer and high expression of netrin-1 (ligand of the DCC (deleted in colorectal cancer) dependence receptor) has been recently demonstrated (recently reviewed in Goldschneider and Mehlen, 2010) . Whereas reinstating the expression of dependence receptors in cancer cells that lost the receptor does not seem a suitable therapeutic approach, blocking survival signaling by interfering with ligand binding in cancer cells is promising in view of the overexpression of netrin in several types of primary and metastatic cancers. The use of decoy molecules such as the full ectodomain of DCC, shorter polypeptides encoding the DCC domains known to interact with netrin-1, or other approaches such as the use of blocking antibodies or peptidemimetics that inhibit netrin-DCC interaction are in preclinical evaluation (Mehlen and Guenebeaud, 2010) . An important open issue that will have to be addressed concerning the targeting of dependence receptor pathways for cancer therapy is the effect of such molecules on normal cells and tissues.
Targeting TICs: a necessity to eradicate cancer?. Despite the significant progress that has been made in cancer diagnosis and therapy, the prognosis of most of the major malignancies remains poor. Apart from acquired resistance to treatment, this has been attributed to either an incomplete elimination of tumor cells or, in cases where complete remission has been observed, a relapse has been interpreted as reactivation of persisting 'dormant' tumor cells. A key feature underlying these phenomena may be related to TICs (also referred to as cancer stem cells), a subset of cells within a tumor that display enhanced selfrenewal and tumorigenic capacity. The existence of TICs is still a matter of controversy that is, at least in part, due to the vast variation in their abundance and proliferation. Although virtually all cells of a melanoma may have cancer stem cell characteristics and medulloblastoma TICs may be highly proliferative (Quintana et al., 2008; Yang et al., 2008) , TICs in general have been described as rather quiescent asymmetrically dividing cells (Holyoake et al., 2001; Guan et al., 2003) . Therefore, as most of the initial and more recently developed tumoricidal drugs target rapidly proliferating cells, TICs would be largely Novel paradigms for cancer therapy V Pavet et al resistant to these cancer therapies and relapse is prone to occur. To date, the only clinical evidence supporting this concept involves acute myeloid leukemia, melanoma and breast cancer patients. When acute myeloid leukemia patients are re-examined after chemotherapy, the persistence of CD34 þ CD38 À cells (proposed to be LICs) predicts a high risk of relapse (van Rhenen et al., 2005) . Similarly, the presence of stemness markers within the tumor cells of melanoma and breast cancer patients (ABCB5 þ and CD44 þ , respectively) correlates with a higher rate of cancer progression and poor prognosis (Shipitsin et al., 2007; Schatton et al., 2008) .
As highlighted above, the eradication of LICs in APL upon treatment with retinoic acid and arsenic supports the concept that agents targeting TICs will lead to complete cure. However, whereas in APL persistence of the PML-RARa fusion protein is apparently required for the survival/proliferation of APL-LICs, the identification of similar key factors in solid tumors that arise from the accumulation of several driver (epi)mutations may pose serious problems. Therefore, particular attention has been paid to target-deregulated self-renewal pathways that have a critical role in TICs of solid tumors. Among those, Hedgehog, Wnt and Notch are currently under evaluation. Recently developed drugs target these signaling cascades preferentially, and some agents are being evaluated in clinical trials (Zhou et al., 2009 ). In addition, surface antigens currently used as markers for the identification of TICs can also be targeted by immunotherapeutic agents or small peptides. These molecules could interfere with signaling pathways orchestrated by such surface molecules and exert therapeutic action. Indeed, agents that target specific surface antigens of TICs are already in phase I/II clinical trials (Zhou et al., 2009) .
It is important to emphasize that natural compounds have also been reported to target TICs selectively, with parthenolide (PTL) being the first such compound described (Guzman et al., 2005 (Guzman et al., , 2007 Steele et al., 2006; Hassane et al., 2008; Kawasaki et al., 2009) . PTL is a sesquiterpene lactone found in feverfew (Chrysanthemum parthenium), which has been traditionally used to treat migraine and rheumatoid arthritis and exerts activity as nuclear factor-kB inhibitor, p53 activator (via ubiquitination of MDM2, mouse double minute 2-p53 binding protein homolog), DNMT1 (DNA (cytosine-5-)-methyltransferase 1) inhibitor and promoter of HDAC1 depletion by proteosome degradation (Gopal et al., 2007) . Using the global transcription response to PTL, a collection of compounds that mimic the effect of PTL were discovered and shown to target acute myeloid leukemia stem cells (Hassane et al., 2008) . Two of these, celastrol (a terpenoid) and 4-hydroxynonenal (a nonterpenoid lipid peroxidation product) are also natural products, whereas one additional hit, 15-deoxy-D12,14-PGJ2, is a prostaglandin derivative. Besides PTL, other TIC-targeting compounds have been recently identified in a chemical screen for molecules that target epithelial cells, which have undergone an epithelial-mesenchymal transition and display a TIC phenotype. Within a library of 16 000 synthetic and natural compounds, four showed consistent selective cytotoxicity for TICs; these are natural products (salinomycin, abamectin and nigericin) or derivatives thereof (etoposide) . Interestingly, salinomycin (a potassium ionophore) was shown to preferentially interfere with TIC viability within breast cancer populations, resulting in the loss of expression of TIC-associated genes that correlated with poor-prognosis tumors.
In summary, most of the classical therapies currently used in the clinic may suffice to eliminate bulk tumor cells, but might not necessarily target TICs, proposed to be the ones having the capacity to repopulate a tumor. Based on the proof-of-concept provided by the APL, it seems rather obvious that tumoricidal strategies need to target TICs to eradicate the disease. However, the picture is not so clear in solid tumors, as for a vast majority of them the nature/ existence of TICs is still under debate. Nevertheless, whether some of the therapeutic approaches discussed in this review can indeed target bulk cells as well as TICs is a topic that deserves to be intensively studied. An emerging area that needs to be further developed involves the thorough identification and characterization of TICs, analyzing their genomes and epigenomes. To describe the molecular signatures that distinguish TICs from the corresponding bulk tumor cells, as well as to identify shared features, will not only allow us to better understand the regulation of TIC stemness, but might also unravel novel targets for drug and epi-drug development.
Non-coding RNAs: potential biomarkers and therapeutic targets to fight cancer?. The development of new technologies for the characterization of the human transcriptome provided evidence that almost 90% of the human genome is transcribed into RNA. Strikingly, whereas only 2% of the transcribed RNAs display protein-coding capacity, the vast majority of the genome is transcribed into non-coding RNAs (ncRNAs). ncRNAs are a very heterogeneous group that has been classified in three families regarding their size: (1) molecules ranging from 18 to 25 nt in length, comprising miRs and small interfering RNAs; (2) molecules from 30 to 300 nt, involving small nucleolar RNAs, piwi RNAs, transfer RNAs, ribosomal RNAs and small-ncRNAs; (3) molecules 4300 nt, referred to as long ncRNAs. The functionality of all transcribed ncRNAs is still a matter of controversy. Although some believe that these molecules are just spurious transcription produced by pervasive transcription, others support that these molecules have critical roles within the cell. Experimental data strongly support that several ncRNAs have indeed biological function. The participation of ncRNAs in translation (transfer RNA, ribosomal RNA), pre-mRNA splicing (small nuclear RNAs) and RNA modifications (small nucleolar RNAs) were described long time ago. Moreover, it has been demonstrated that ncRNAs are expressed in a developmentally regulated manner and their role in chromatin modification, transcriptional regulation and post-transcriptional stabilization/degradation of mRNAs has been recently discovered (for a recent review, see Rana, 2007) .
Importantly, ncRNAs affect key cellular processes that are altered in cancer, such as cell differentiation, Novel paradigms for cancer therapy V Pavet et al proliferation, death and survival. The H19 RNA was the first cancer-related ncRNA described whose expression is deregulated in cancer. Some reports show that in certain cancer cells, H19 expression decreases tumorigenicity, thus acting as tumor suppressor. Conversely, other studies indicate that this ncRNA is elevated in different cancer types, in which it seems to display oncogenic activity. These results highlight the fact that the expression level of a given ncRNA by itself might not be sufficient for predicting its final oncogenic/tumor-suppressor capacity. Indeed, the final effect exerted by ncRNAs may be dependent on cell type, developmental stage and expression of cell/tissue-specific isoforms of the ncRNA or expression of specific ncRNA-binding proteins and target mRNAs. Indeed, it was recently reported that the H19 ncRNA is a primary precursor encoding at least one miR (miR-675). Whether this or other miRs and/or ncRNAs processed from H19 precursor are responsible for the tumorigenic properties of this transcript remains to be established (Cai and Cullen, 2007) .
Although the aberrant expression of several small and long ncRNAs has been reported in cancer, and some can be already used as molecular markers of early disease (for example, DD3 RNA in prostate cancer) or prognostic factors (for example, MALAT-1 RNA in lung cancer), their functional role in the onset/progression of the disease remains largely elusive. Despite this lack of knowledge, the observation that ncRNAs can regulate the tumor response to different therapeutic drugs revealed their importance not only as biomarkers but also as potential therapeutic targets (Persson et al., 2009) . As an example, the overexpression of the long ncRNA PCGEM1 (prostate cancer gene expression marker 1) in prostate cancer models confers resistance against sodium selenite and doxorubicin, thus supporting the escape of prostate cancer cells from drug-induced apoptosis (Srikantan et al., 2000) . Among all ncRNAs, miRs are the ones that have been more extensively studied to date. These molecules have been shown to display pro-and anti-tumorigenic capacity, to be either targets or regulators of main cancerderegulated pathways (that is, p53, c-Myc among others), and to modulate apoptotic responses. Supporting this line of thought, very recent reports have proven that modifying the levels of single miRs in vivo can directly induce a reduction of tumor growth as well as regulate sensitivity to apoptosis in cancer cells (Esquela-Kerscher et al., 2008; Idogawa et al., 2009) . Similarly, certain miRs can modulate the response of cancer cells to TRAIL in vitro and in preclinical models (Ovcharenko et al., 2007; Garofalo et al., 2009) .
In summary, the presently available data support the notion that ncRNAs are regulators of cell homeostasis and have central roles in a variety of processes that are relevant to cancer cell growth and survival. Considering that a single ncRNA can potentially orchestrate the expression of several proteins engaged in different molecular pathways, modulating the expression of a single RNA could simultaneously target different molecular cascades. Moreover, it has been recently shown that ncRNAs can direct epigenetic modifications including DNA methylation and post-translational modifications of histones (Costa, 2008 ).
This suggests that by modulating ncRNA levels, the epigenetic makeup of a cell could be potentially modified, thus opening new avenues for epigenetic therapy. Nonetheless, several open questions remain to be answered before ncRNAs can be used as therapeutics. For example, it has been demonstrated that some miRs either block or induce the translation of a given mRNA, depending on the proliferative status of the cell (Vasudevan et al., 2007) . Moreover, although bioinformatic prediction indicates that a given miR could have hundreds of potential target mRNAs, the definition of the real target(s) within different cells and the molecular basis of this selection have remained obscure. As miR expression signatures are associated with tumor classification, prognosis, diagnosis and treatment response, several clinical trials are currently ongoing with the aim of profiling or identifying ncRNAs in several types of cancer (http://clinicaltrials.gov). The anticipated insight from current clinical trials and ongoing efforts to unravel the function and regulation of ncRNAs will not only help us to better understand cellular circuitries, but may provide additional biomarkers and a novel class of therapeutic targets to fight cancer.
Conclusions
Although the existence of neoplastic transformation has been acknowledged for centuries, treatment was restricted to surgery and radiotherapy until the 1950s. Starting in the 1980s, our increasing understanding of (cancer) cell biology and the mechanisms of tumorigenesis/cancer progression allowed the development of 'cancer-related therapies'. Although such mechanistic studies are intensified and enter a new dimension by the application of genome-wide technologies through a plethora of international consortia (for example, International Cancer Genome Consortium (ICGC; http:// www.icgc.org/); International Human Epigenome Consortium (IHEC; http://www.epigenome-noe.net/WWW/ ihec/index.php)), today's efforts include the discovery of molecules and regulatory pathways that allow the design of 'cancer-targeted therapies', thus restricting side effects, and improving life quality and overall survival.
That cancer remains one of the largest causes of death worldwide with a striking 13% of all human deaths per year asks for a reflection about the principle concepts of cancer therapy. Clearly, despite improvements, the critical issue of targeting cancer cells with high selectivity has by far not been reached for most cancers, although some very specific cases are often presented as breakthrough in cancer therapy, such as APL and CML (see discussion above). In this study we attempted to critically review present paradigms for cancer-selective therapy and their status of development. From this analysis we derive three conceptual remarks. First, it is unlikely that single compound satisfying the criteria of selectivity and efficacy can be found. This supports the development of combination therapies that allow for dose reduction at similar efficacy, due to synergistic action. Moreover, the combination of drugs exerting their effect through different therapeutic targets minimizes the risk of resistance development. An attractive option in this respect is the generation of compounds with multiple desired activities, such as a recently described epi-drug that concomitantly targets three different chromatin-modifying enzymes (WO 2008/125988 A1) (HDAC, sirtuin and DNMT1 inhibitory activity). Second, should there be a general cancer eradication pathway that has been developed during evolution, we need to understand the mechanistic basis and develop tools to exploit this selectivity for therapy. The apoptotic TRAIL signaling pathway is a very promising candidate in this respect, and intensive research and drug development is ongoing at both pharmaceutical and academic research laboratories. Surprisingly, the mechanisms accounting for the cancer selectivity of TRAIL have still remained largely enigmatic. Third, the existence of TICs needs to be validated and their response to current and future therapeutic paradigms has to be considered.
Novel, less-advanced therapeutic concepts are at various steps of development or validation, including the conceptually attractive death-inducing 'dependence receptors'. At the horizon, the world of ncRNAs emerges with all the promises that a new world can offer.
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